StockSelector.com
  Research, Select, & Monitor Monday, May 21, 2018 6:56:41 AM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Ligand Pharmaceuticals, Inc.$194.99$3.852.01%

  Quote | Ranking | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

 Ligand to Report Fourth Quarter and Full Year 2017 Results on February 21st
   Monday, February 05, 2018 4:01:00 PM ET

Ligand Pharmaceuticals Incorporated (LGND ) announced today plans to report fourth quarter and full year 2017 financial results on February 21, 2018. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.

Fourth Quarter and Full Year 2017 Earnings Call
                    
What:                                                      Ligand conference call to discuss financial results and provide
                                                           general business updates
                                                            
When:                                                      Wednesday, February 21, 2018
                                                            
Time:                                                      4:30 p.m. Eastern time (1:30 p.m. Pacific time)
                                                            
Conference Call:                                           (833) 591-4752 within the U.S.
                                                           (720) 405-1612 outside the U.S.
                                                           Conference ID - 2391528
                                                            
Webcast:                                                   Live conference call webcast and replay accessible at www.ligand.com
                                                            

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue. Ligand’s Captisol(R) platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. OmniAb(R) is a patent-protected transgenic animal platform used in the discovery of fully human mono- and bispecific therapeutic antibodies. Ligand has established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Novartis, Amgen, Merck, Pfizer, Celgene, Gilead, Janssen, Baxter International and Eli Lilly.

Follow Ligand on Twitter @Ligand_LGND.

http://cts.businesswire.com/ct/CT?id=bwnews&sty=20180205005769r1&sid=cmtx6&distro=nx&lang=en

View source version on businesswire.com: http://www.businesswire.com/news/home/20180205005769/en/

SOURCE: Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated 
Todd Pettingill 
investors@ligand.com 
(858) 550-7893 
@Ligand_LGND 
or 
LHA 
Bruce Voss 
bvoss@lhai.com 
(310) 691-7100


Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2018 StockSelector.com. All rights reserved.